Export

ATC codes: L01DB01
EMLc
Indication
Anaplastic large cell lymphoma, ALK-positive ICD11 code: 2A90.A
INN
Doxorubicin
Medicine type
Chemical agent
List type
Complementary (EML)
(EMLc)
Formulations
Parenteral > General injections > IV: 10 mg in vial (hydrochloride) ; 50 mg in vial (hydrochloride) ; 2 mg per mL in 5 mL vial (hydrochloride) ; 2 mg per mL in 25 mL vial (hydrochloride)
EML status history
First added in 2023 (TRS 1049)
Sex
All
Age
Also recommended for children
Therapeutic alternatives
The recommendation is for this specific medicine
Patent information
Patents have expired in most jurisdictions
Tags
Wikipedia
DrugBank
Summary of evidence and Expert Committee recommendations
The Expert Committee recommended the current listings of cyclophosphamide, cytarabine, dexamethasone, doxorubicin, etoposide, ifosfamide, methotrexate, prednisolone and vinblastine on the complementary list of the EML and EMLc be extended to include the new indication of anaplastic large cell lymphoma (ALCL). These medicines are recognized as part of the standard of care for ALCL. Their benefits and harms were accepted as being well established from use in other indications in children and in adults. Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the inclusion of an additional dose forms of doxorubicin (2 mg/mL (hydrochloride) in 5 mL, 25 mL vial) to the EML and EMLc.